Table 1.
Participant characteristics
| Characteristic | Control (n=12) | MS (n=16) |
|---|---|---|
| Age (yr) | 68±3 | 69±4 |
|
| ||
| Time after menopause (yr) | 10±3 | 12±4 |
|
| ||
| MS diagnosis (yr) | - | 10±5 |
|
| ||
| Weight (kg) | 75.3±12 | 78.5±10 |
|
| ||
| Height (cm) | 155±15 | 153±12 |
|
| ||
| Body mass index (kg/m2) | 32.6±5 | 34.5±6 |
|
| ||
| Waist-hip ratio | 0.82±0.06 | 0.93±0.07* |
|
| ||
| Medications (%) | ||
| ACE inhibitor | 9 | 25 |
| HMG-CoA reductase inhibitor | 5 | 78* |
| Diuretic | 18 | 60* |
| Acid acetylsalicylic | 8 | 38* |
| ARBs | 0 | 45* |
| Oral hypoglycemiants | 0 | 95* |
Values are presented as mean±standard deviation unless otherwise indicated.
MS, metabolic syndrome; ACE, angiotensin-converting-enzyme; HMG-CoA, 3-hydroxy-3-methyl-glutaryl coenzyme A; ARBs, angiotensin II receptor blockers.
*
P<0.05 vs. C group.